Discovery of the Impact of Targeted Lung Denervation (TLD) on the Severe and Very Severe COPD Population

NCT03213080 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2019-02-18

No results posted yet for this study

Summary

The DISCOVER TLD study is a multicenter, prospective, single-arm study designed to record the clinical outcomes of the CE-marked Nuvaira™ Lung Denervation System, in a subset of its CE-marked approved indication. This study is being conducted in Europe.

Conditions

Interventions

DEVICE

Targeted Lung Denervation (TLD)

Targeted Lung Denervation (TLD) procedure.

Sponsors & Collaborators

  • Nuvaira, Inc.

    lead INDUSTRY

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-31
Primary Completion
2021-09-30
Completion
2021-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03213080 on ClinicalTrials.gov